Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)

Sponsor
King Faisal Specialist Hospital & Research Center
Study ID
NCT02919371
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Sunitinib — DRUG
    Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days
  • Bevacizumab — DRUG
    Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle

Study Details

Combined sunitinib and bevacizumab in advanced renal cell carcinoma.

Key Dates

First listed
Sep 29, 2016
Start date
Dec 31, 2014
Status verified
Aug 2018
Primary completion
Dec 31, 2020
Completion
Dec 31, 2021

Study Design

Enrollment
77 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Sunitinib and Bevacizumab Arm
    Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell carcinoma (CASA)Combined Alternating Sunitinib and Bevacizumab

Primary Outcome Measure

Bevacizumab maximum tolerated dose, in combination with sunitinib [ Time Frame: 12 weeks from enrolling patient # 6 ]

Central Contacts

Related Studies